-
Presenter Profile: Towards Innovative and Equitable Care in Youth-Onset Type 2 Diabetes
Stephanie T. Chung, MBBS, previews a presentation at the 84th Scientific Sessions. Attendees in Orlando can watch the session in-person Monday, June 24, at 8:00 a.m. ET, and select recordings will be available on the meeting’s virtual platform after the live presentations.
-
SURMOUNT-OSA investigators will unveil new findings in obesity-related OSA
Atul Malhotra, MD, will be among the researchers sharing phase 3 clinical trial data showing the potential of a dual gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist used in the treatment of type 2 diabetes as a potential therapy for obesity-related obstructive sleep apnea (OSA). SURMOUNT-OSA evaluated how tirzepatide injection affected the…
-
STEP-HFpEF trial results show benefit of GLP-1 receptor agonists for patients with heart failure and diabetes
“Obesity is not just a comorbidity in people with heart failure with preserved ejection fraction but is a target for treatment,” said cardiac surgeon Subodh Verma, MD, PhD, FRCSC, one of the experts who will discuss new data from the STEP-HFpEF and STEP-HFpEF-DM trials.
-
Symposium will focus on how dietitians and diabetes educators can support patients on GLP-1-based therapies
Maureen Chomko, RDN, CDCES, and Colleen Dawkins, FNP-C, RDN, CSOWM, will explain how dietitians and diabetes educators can help screen patients for their eligibility for these drugs, educate patients on how to take these medications, and help them understand cost implications.
-
Panel to explore evidence and provide recommendations for using ‘Category X’ diabetes drugs during pregnancy
Ira J. Goldberg, MD, and other experts will review diabetes medications that have been associated with fetal complications and current recommendations for their discontinued use during pregnancy, despite significant maternal benefits outside of pregnancy.
-
Investigators to share results from Part 1 of CATALYST study of hypercortisolism in type 2 diabetes
Investigators including John B. Buse, MD, PhD, will present findings from a study of the prevalence of hypercortisolism in patients with an A1C of ≥7.5% despite receiving multiple standard-of-care therapies.
-
Symposium to discuss how primary care providers can elevate their practice for patients with diabetes
An ADA Primary Care Council symposium, featuring experts including Pamela Stamm, PharmD, BCPS, BCACP, CDCES, FASHP, FCCP, aims to help practitioners identify ways they can deliver more consistent, high-quality care in order to improve outcomes, reduce complications, and decrease hospitalizations.
-
Experts to debate roles of immune cells and beta-cells in driving progression of type 1 diabetes
Jamie L. Felton, MD, will make the case that immune cells play a more significant role in type 1 diabetes progression, while Edward A. Phelps, PhD, will take the position that beta-cells are more active participants in disease progression.
-
Researchers to explain the association between GLP-1 receptor agonists and severe side effects in obesity treatment
Daniel J. Drucker, MD, and other panelists will discuss the relative risks and strategies for mitigating the severe side effects of GLP-1 receptor agonists, among them pancreatitis.
-
Presenter Profiles: Liver Health in Diabetes
Kenneth Cusi, MD, and Karen D. Corbin, PhD, RD, preview a presentation at the 84th Scientific Sessions. Attendees in Orlando can watch the session in-person Friday, June 21, at 5:30 p.m. ET, and select recordings will be available on the meeting’s virtual platform after the live presentations.